KR102921161B1 - 펜타시클릭 화합물의 염 및 이의 결정 - Google Patents

펜타시클릭 화합물의 염 및 이의 결정

Info

Publication number
KR102921161B1
KR102921161B1 KR1020217025603A KR20217025603A KR102921161B1 KR 102921161 B1 KR102921161 B1 KR 102921161B1 KR 1020217025603 A KR1020217025603 A KR 1020217025603A KR 20217025603 A KR20217025603 A KR 20217025603A KR 102921161 B1 KR102921161 B1 KR 102921161B1
Authority
KR
South Korea
Prior art keywords
thieno
chemical formula
diffraction
compound
crystal
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020217025603A
Other languages
English (en)
Korean (ko)
Other versions
KR20210135223A (ko
Inventor
겐시 요시다
요시아키 오하시
다마키 호시카와
노부아키 사토
이쿠오 구시다
Original Assignee
에자이 알앤드디 매니지먼트 가부시키가이샤
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 에자이 알앤드디 매니지먼트 가부시키가이샤 filed Critical 에자이 알앤드디 매니지먼트 가부시키가이샤
Publication of KR20210135223A publication Critical patent/KR20210135223A/ko
Application granted granted Critical
Publication of KR102921161B1 publication Critical patent/KR102921161B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains four or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
KR1020217025603A 2019-03-05 2020-03-03 펜타시클릭 화합물의 염 및 이의 결정 Active KR102921161B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JPJP-P-2019-039349 2019-03-05
JP2019039349 2019-03-05
PCT/JP2020/008889 WO2020179781A1 (ja) 2019-03-05 2020-03-03 五環式化合物の塩およびそれらの結晶

Publications (2)

Publication Number Publication Date
KR20210135223A KR20210135223A (ko) 2021-11-12
KR102921161B1 true KR102921161B1 (ko) 2026-02-02

Family

ID=72337486

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020217025603A Active KR102921161B1 (ko) 2019-03-05 2020-03-03 펜타시클릭 화합물의 염 및 이의 결정

Country Status (11)

Country Link
US (1) US11420980B2 (https=)
EP (1) EP3936189A4 (https=)
JP (1) JP7508441B2 (https=)
KR (1) KR102921161B1 (https=)
CN (1) CN113646046B (https=)
AU (1) AU2020233452B2 (https=)
BR (1) BR112021015979A2 (https=)
CA (1) CA3129764A1 (https=)
MX (1) MX2021009774A (https=)
TW (2) TWI870286B (https=)
WO (1) WO2020179781A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020179780A1 (ja) 2019-03-05 2020-09-10 エーザイ・アール・アンド・ディー・マネジメント株式会社 五環式複素環化合物
PT119624A (pt) * 2024-07-29 2026-01-29 Silva Escada Guilherme Máquina modular para a dobragem de tubos de pvc

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4187306A (en) * 1977-07-26 1980-02-05 Bayer Aktiengesellschaft Benzodiazepine-diones, a process for their production and their use as medicaments
DD258234A1 (de) 1987-03-05 1988-07-13 Univ Leipzig Verfahren zur herstellung von pyrido/3',2':4,5/thieno/2,3-e/imidazo-/1,2-c/pyrimidinen sowie strukturanaloger -pyrimido/1,2-c/pyrimidine bzw. -1,3-diazepino/1,2-c/pyrimidine
RU2117670C1 (ru) 1988-10-31 1998-08-20 Эйсай Ко., Лтд. Производные триазоло[1,4]диазепина и способы их получения
TW197442B (https=) * 1990-02-08 1993-01-01 Pfizer
US5621100A (en) * 1992-07-24 1997-04-15 Cephalon, Inc. K-252a derivatives for treatment of neurological disorders
US5756494A (en) * 1992-07-24 1998-05-26 Cephalon, Inc. Protein kinase inhibitors for treatment of neurological disorders
KR100203456B1 (ko) * 1995-06-20 1999-06-15 한승수 디하이드로에보디아민-에이치씨1를 유효성분으로 함유하는 알츠하이머병에 의한 치매 치료제
CL2004000348A1 (es) 1997-04-15 2005-01-14 Cephalon Inc & Kyowa Hakko Kog Compuesto derivado de estaurosporina bis-n-sustituida, util para potenciar la funcion de neuronas colinergicas, estriadas, del prosencefalo basal y sensoriales.
CL2004000352A1 (es) 1998-05-26 2005-05-27 Cephalon Inc & Kyowa Hakko Kog Uso de compuestos derivados de estaurosporina para potenciar la funcion de neuronas colinergicas, estriadas, de prosencefalo basal y sensoriales.
FR2779652B1 (fr) 1998-06-15 2001-06-08 Sod Conseils Rech Applic Utilisation de diazepines pour la preparation de medicaments destines a traiter les etats pathologiques ou les maladies dans lesquels un des recepteurs de la somatostatine est implique
US8252520B2 (en) 2002-10-11 2012-08-28 Taivex Therapeutics Corporation Methods and compounds for inhibiting Hec1 activity for the treatment of proliferative diseases
AU2005299031B2 (en) 2004-10-20 2011-11-10 F. Hoffmann-La Roche Ag Halogen substituted benzodiazepine derivatives
US9314318B2 (en) * 2008-08-26 2016-04-19 Zest Ip Holdings, Llc Dental anchor apparatus and method
JP6557441B1 (ja) * 2017-09-07 2019-08-07 エーザイ・アール・アンド・ディー・マネジメント株式会社 五環式化合物
WO2020179780A1 (ja) 2019-03-05 2020-09-10 エーザイ・アール・アンド・ディー・マネジメント株式会社 五環式複素環化合物

Also Published As

Publication number Publication date
EP3936189A1 (en) 2022-01-12
JP7508441B2 (ja) 2024-07-01
BR112021015979A2 (pt) 2021-10-05
KR20210135223A (ko) 2021-11-12
US11420980B2 (en) 2022-08-23
CN113646046A (zh) 2021-11-12
TWI849070B (zh) 2024-07-21
MX2021009774A (es) 2021-09-08
JPWO2020179781A1 (https=) 2020-09-10
CN113646046B (zh) 2024-05-17
AU2020233452A1 (en) 2021-09-02
EP3936189A4 (en) 2022-12-14
TW202430531A (zh) 2024-08-01
WO2020179781A1 (ja) 2020-09-10
AU2020233452B2 (en) 2025-04-10
TW202100531A (zh) 2021-01-01
US20210024541A1 (en) 2021-01-28
TWI870286B (zh) 2025-01-11
CA3129764A1 (en) 2020-09-10

Similar Documents

Publication Publication Date Title
JP2024037770A (ja) Ｓａｒｍ１阻害剤
RU2754557C1 (ru) Пентациклическое соединение
JP2021528488A (ja) Ｓａｒｍ１阻害剤
WO2014179303A1 (en) Amyloid precursor protein mrna blockers for treating down syndrome and alzheimer's disease
KR102921161B1 (ko) 펜타시클릭 화합물의 염 및 이의 결정
EP1458711A1 (en) Use of oxindole derivatives in the treatment of dementia related diseases, alzheimer s disease and conditions associated with glycogen synthase kinase-3
RU2820938C2 (ru) Соль пентациклического соединения и его кристалл
CN108658976B (zh) 一类新型吡唑并[4,3-c]吡啶-4(5)-酮布鲁顿激酶抑制剂
KR102352624B1 (ko) LRRK2 (Leucine Rich Repeat Kinase 2) 키나제 억제제로서의 피리도피리미딘 유도체 화합물
WO2026035920A1 (en) (2-oxo-2h-chromen-3-yl) scaffold based carboxamide analogs as potent inhibitors of tau protein fibrils
BR112020003197B1 (pt) Composto pentacíclico
HK40022802B (en) Pentacyclic compound
HK40022802A (en) Pentacyclic compound

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

D22 Grant of ip right intended

Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D22-EXM-PE0701 (AS PROVIDED BY THE NATIONAL OFFICE)

PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

F11 Ip right granted following substantive examination

Free format text: ST27 STATUS EVENT CODE: A-2-4-F10-F11-EXM-PR0701 (AS PROVIDED BY THE NATIONAL OFFICE)

PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

U12 Designation fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U12-OTH-PR1002 (AS PROVIDED BY THE NATIONAL OFFICE)

Year of fee payment: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

Q13 Ip right document published

Free format text: ST27 STATUS EVENT CODE: A-4-4-Q10-Q13-NAP-PG1601 (AS PROVIDED BY THE NATIONAL OFFICE)